Ian Nicholson is Chair of the Remuneration Committee. Ian has over 35 years’ international experience in management and transactions within the life sciences sector including as chairman of Bioventix plc, as operating partner at London-based Advent Life Sciences LLP, and 8 years as CEO of the privately held anti-fungal drug development company F2G Limited. Ian has worked extensively in licensing, mergers and acquisitions and market development in the UK, Europe and the USA.
Ian Nicholson
Latest news
-
LifeArc launches £40m research centres that will unlock new tests, treatments and cures for people living with rare diseases
Read more: LifeArc launches £40m research centres that will unlock new tests, treatments and cures for people living with rare diseases -
First-of-a-kind plan announced to get more children access to cutting-edge, proven gene therapy treatments for rare diseases
Read more: First-of-a-kind plan announced to get more children access to cutting-edge, proven gene therapy treatments for rare diseases -
New £6.2m partnership will help to eliminate a deadly disease affecting children and vulnerable people in Kenya
Read more: New £6.2m partnership will help to eliminate a deadly disease affecting children and vulnerable people in Kenya